A-shares closed · 港股休市 Quotes 行情 · 25 Sep 17:19 CST
28 Sep 2026 · 00:34 CST Terminal Access 终端入口 →
600594.SH上海证券交易所 · 主板 Main

Yibai Pharmaceutical 益佰制药

Traditional Chinese Medicine 中药Ⅱ
¥3.61−¥0.06 · −1.63%Delayed 行情延迟 · 24 Sep 2026 · 16:14 CST · CNY
Open 开盘
¥3.68
High 最高
¥3.71
Low 最低
¥3.59
Prev Close 昨收
¥3.67
Volume 成交量
1,585.9万股
Turnover 成交额
¥5,761.6万
Mkt Cap 总市值
¥28亿
P/E 市盈率
−7.3×
Recent Activity 近期动态All Filings 全部公告 →

3 significant filings since 31 May 2026: 1 on regulatory action, 1 on earnings pre-announcement and 1 on buyback. The latest, on 1 Aug 2026: 贵州益佰制药股份有限公司关于收到贵州省药品监督管理局《行政处罚告知书》的公告.
自 31 May 2026 起有 3 份重大公告:regulatory action 1 份、earnings pre-announcement 1 份、buyback 1 份。最新一份(1 Aug 2026):贵州益佰制药股份有限公司关于收到贵州省药品监督管理局《行政处罚告知书》的公告。

Price History 价格走势

250 trading days 个交易日 · High 最高 ¥5.06 · Low 最低 ¥2.95
3.003.504.004.505.00
Volume 成交量
2.27亿
Sep 25Dec 25Mar 26Jun 26Sep 26

Against Its Own History 与自身历史比较

−7.3×
Median 中值 26.9× · Range 区间 14.3× to 43.4× · 6 periods 期
1.36×
Median 中值 1.33× · Range 区间 0.87× to 1.93× · 20 periods 期

Period by Period 逐期

Period 报告期Close at Period End 期末收盘TTM EPS 滚动每股收益 BPS 每股净资产
30 Jun 2026 中报¥2.97−¥0.50—¥2.661.12×
31 Mar 2026 一季报¥3.96−¥0.45—¥2.731.45×
31 Dec 2025 年报¥3.98−¥0.42—¥2.761.44×
30 Sep 2025 三季报¥4.08−¥0.30—¥3.031.34×
30 Jun 2025 中报¥3.85−¥0.29—¥3.121.23×
31 Mar 2025 一季报¥3.43−¥0.33—¥3.131.10×
31 Dec 2024 年报¥3.56−¥0.40—¥3.141.13×
30 Sep 2024 三季报¥3.81−¥0.30—¥3.341.14×
30 Jun 2024 中报¥3.00−¥0.17—¥3.440.87×
31 Mar 2024 一季报¥4.75−¥0.01—¥3.561.34×
31 Dec 2023 年报¥5.69¥0.1343.4×¥3.641.56×
30 Sep 2023 三季报¥5.80−¥0.58—¥4.061.43×
30 Jun 2023 中报¥5.27−¥0.55—¥4.011.32×
31 Mar 2023 一季报¥5.73−¥0.56—¥3.901.47×
31 Dec 2022 年报¥5.53−¥0.55—¥3.611.53×
30 Sep 2022 三季报¥5.05¥0.1828.1×¥4.631.09×
30 Jun 2022 中报¥5.60¥0.2522.6×¥4.541.23×
31 Mar 2022 一季报¥7.73¥0.2827.4×¥4.491.72×
31 Dec 2021 年报¥8.13¥0.3126.4×¥4.211.93×
30 Sep 2021 三季报¥5.91¥0.4114.3×¥4.491.32×

Consensus Forward EPS 机构预测每股收益

No broker forecasts for this company yet 暂无机构预测

Not Computed 未计算
  • Dividend Yield 股息率
  • Free Cash Flow 自由现金流
  • EV/EBITDA